| Index | — | P/E | — | EPS (ttm) | — | Insider Own | — | Shs Outstand | 48.06M | Perf Week | 1.19% |
| Market Cap | 938.58M | Forward P/E | — | EPS next Y | -4.77 | Insider Trans | — | Shs Float | 23.66M | Perf Month | -5.79% |
| Enterprise Value | 646.58M | PEG | — | EPS next Q | -1.13 | Short Float | 13.87% | Perf Quarter | -2.15% | ||
| Income | -149.00M | P/S | — | EPS this Y | — | Short Ratio | 12.92 | Perf Half Y | — | ||
| Sales | 3.00M | P/B | 2.23 | EPS next Y | — | ROA | -18.82% | Short Interest | 3.28M | Perf YTD | -2.35% |
| Book/sh | 8.76 | P/C | 3.02 | EPS next 5Y | — | ROE | 177.71% | 52W High | 29.05 -32.77% | Perf Year | — |
| Cash/sh | 6.47 | P/FCF | — | EPS past 3/5Y | — | ROIC | -20.66% | 52W Low | 15.10 29.34% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 7.30% 7.42% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.55 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 11.36 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 48.88 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 11.36 | EPS Q/Q | 74.30% | SMA20 | 4.95% | Beta | 1.31 | Target Price | 36.60 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | — | SMA50 | -9.81% | Rel Volume | 0.97 | Prev Close | 19.54 |
| Employees | 100 | LT Debt/Eq | 0.05 | Earnings | Nov 04 | SMA200 | -0.93% | Avg Volume | 265.76K | Price | 19.53 |
| IPO Date | May 08, 2026 | Option/Short | No / Yes | EPS/Sales Surpr. | -7.92% — | Net Debt/EBITDA | — | Volume | 258,944 | Change | -0.05% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Initiated | UBS | Buy | $27 |
| Oct-08-26 | Initiated | Raymond James | Outperform | $42 |
| Aug-27-26 | Initiated | H.C | Buy | $44 |
| Jun-02-26 | Initiated | Wedbush | Outperform | $30 |
| Jun-02-26 | Initiated | Oppenheimer | Outperform | $40 |
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | |
|---|---|---|
| Total Revenue | 3 | |
| Cost of Goods Sold Incl. D&A | 0 | |
| Gross Profit | 3 | |
| Selling, General and Administrative Excl. Other | 38 | |
| Research and Development | 127 | |
| Other Operating Expense | -1 | |
| Operating Income | -161 | |
| Interest Expense | 0 | |
| Unusual Expense | — | |
| Non-Operating Income (Expense) | 12 | |
| Net Income Before Taxes | -150 | |
| Income Taxes | -1 | |
| Consolidated Net Income | -149 | |
| Net Income From Continuing Operations | -149 | |
| Net Income | -149 | |
| EPS (Recurring) | -5.39 | |
| EPS (Basic, Before Extraordinaries) | -5.39 | |
| EPS (Diluted) | -5.39 | |
| EBITDA | -145 | |
| Other After Tax Adjustments | — | |
| Stock Option Compensation Expense | — | |
| Price To Earnings Ratio | — | |
| Price To Sales Ratio | — | |
| Gross Margin | 100.00 | |
| Operating Margin | -5,366.67 | |
| Net Margin | -4,966.67 | |
| Shares Outstanding | 28 | |
| Market Capitalization | — | |
| Operating Lease Expense | — |